Purpose: Acne is a skin condition of the pilosebaceous unit that affects mainly the face, chest and trunk. Approximately 50% of subjects with facial acne also have acne of the trunk. This study investigated the clinical benefit of a cleansing gel containing salicylic acid 2%, zinc gluconate 0.2% and lipohydroxy acid 0.05% in truncal acne after 84 days of daily use. Materials and Methods: A single center, open label, non-randomized study with 51 subjects with mild to moderate truncal acne was conducted. Thirty-five (35) subjects completed the study; mean age was 23 years. Inflammatory and non-inflammatory lesions, Transepidermal water loss (TEWL) and local tolerance were assessed at baseline, Day 42 and Day 84 and total lesion count was calculated. Results: The total lesion count was significantly reduced (p< 0.05) after 42 days (− 21.5%) and 84 days (− 56.3%). Non-inflammatory lesions were significantly decreased after 84 days (− 64.0%) only, while inflammatory lesions were decreased at Day 42 (− 29.2%), and Day 84 (− 48.2%). A statistically significant skin barrier improvement was observed at Day 84 (− 21.26%). No adverse events or relevant local intolerance were reported. Conclusion: The use of the cleansing gel studied was effective in improving mild to moderate truncal acne and contributed to the skin barrier improvement. The product was well tolerated. Clintrial Data Base Identifier: NCT05584150.
19 March 2026 in International Journal of Dermatology
S(Sensitive Skin Is Defined By The Occurrence Of Unpleasant Sensations In Response To Stimuli That Should Not Normally Provoke Such Sensations. The Causative Factors Of Skin Sensitivity Include Physical (Heat
Sensitive Skin Is Defined By The Occurrence Of Unpleasant Sensations In Response To Stimuli That Should Not Normally Provoke Such Sensations. The Causative Factors Of Skin Sensitivity Include Physical (Heat
+6
Self-Reported Skin Sensation by People Who Have Experienced Containment During COVID-19 Pandemic
11 July 2023 in Clinical, Cosmetic and Investigational Dermatology
Introduction: Intolerance to dermocosmetics is frequent in subjects with allergic contact dermatitis (ACD). A dermocosmetic (DC) was developed to restore the natural skin barrier, to reduce skin inflammation and to improve sensitive skin in ACD. Objective: To assess the benefit of a DC in subjects with an allergic background and intolerance to cosmetic care, or with sensitive skin. Materials and Methods: In this open-label study, 107 subjects above 16 years of age applied DC on the face twice a day for 28 days. Assessments at Days 0, 14 and 28, included skin sensitivity, stinging test, local tolerance, transepidermal water loss (TEWL), skin hydration, inflammatory biomarkers (IL-1α, IL-1RA, PGE2) using tape stripping and subject satisfaction. Results: 88% were women and mean age was 42.0± 15.0 years. Skin sensitivity at inclusion scored 5.9± 0.35; 46% had ACD, 95% skin irritation, 92% sensitive skin and 88% intolerance to cosmetics. A significant (p< 0.0001) 85% decrease of frequency and intensity of the composite score was observed at both endpoints. Stinging scores significantly (p< 0.0001) decreased from 3.9 at baseline to 2.4 at Day 14 and 1.4 at Day 28; 77% and 81% of subjects reported improved skin reactivity at Day 14 and Day 28, respectively. Similar improvements were noted in the frequency and intensity of irritation, erythema, stinging, burning and discomfort. TEWL, skin hydration and inflammatory biomarker levels significantly (p< 0.0001) improved. Overall subject satisfaction (85%) and tolerance (investigators: 99%, subjects: 97%) were high. Conclusion: DC significantly reduced the frequency and intensity of facial skin intolerability and sensitivity in subjects with skin intolerant to skin care products. Clinicaltrials.gov Identifier: NCT05487937.
1 January 2023 in Clinical, Cosmetic and Investigational Dermatology
Background: Eyelid eczema (EE) is frequently observed in patients with an allergic or atopic diathesis. As for atopic eczema, restoring the skin barrier of the periocular region together with relieving clinical signs and symptoms is important in the management of EE. This study assessed the benefit and tolerance of a dedicated dermocosmetic (DC) in subjects with EE. Materials and Methods: Open-label study in adults with EE and sensitive skin. The DC was applied twice daily for 28 days. Dermatological signs (eczema, desquamation/dryness, erythema, swelling, roughness) and symptoms (itching, prickling, heat/burning sensation, tightness) on the periorbital region, as well as ophthalmological evaluation were assessed at Day 0, 14 and 28. Subjects assessed quality of life (QOL) using DLQI, the perceived benefit and cosmetic acceptability of the DC. Results: Overall, 41 subjects were included; 59% were women. The mean age was 52.4± 15.8 years; all subjects had periorbital sensitive skin. The DC immediately reduced the intensity of itching, prickling, heat/burning sensation and tightness. Clinical signs and symptoms had all significantly (p< 0.001) improved by Day 14 and were sustained to Day 28. The DC significantly (p< 0.001) improved the perception of irritation (73%) and swelling (66%) while soothing (59%) the periorbital skin regions at Day 28. QOL had improved at Day 28 (0.82± 1.0) compared to Day 0 (4.17± 2.23). No local adverse reactions were reported. Ophthalmological examinations paralleled the excellent dermatological tolerance of DC. Discussion: The tested DC is highly efficacious in reducing clinical signs and symptoms of eyelid eczema and was well tolerated. ClinicalTrials.gov Identifier: NCT05540496.
14 May 2026 in Annales de Dermatologie et de Vénéréologie